A study to learn how safe and tolerable odronextamab and cemiplimab are in adult patients with B-cell malignancies

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-508209-25-00

Acronym

R1979-ONC-1504

Enrollment

Registered

2024-03-25

Start date

2024-04-19

Completion date

Unknown

Last updated

2025-11-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

B-Cell Non-Hodgkin’s Lymphoma (B-NHL)

None listed

Sex/Gender

All

Age

18 Years to No maximum

Austria, Poland, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026